title: Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary.
authors.forename: Philip
authors.initials: P
authors.lastname: Hooper
authors.forename: Marie Carole
authors.initials: MC
authors.lastname: Boucher
authors.forename: Alan
authors.initials: A
authors.lastname: Cruess
authors.forename: Keith G
authors.initials: KG
authors.lastname: Dawson
authors.forename: Walter
authors.initials: W
authors.lastname: Delpero
authors.forename: Mark
authors.initials: M
authors.lastname: Greve
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kozousek
authors.forename: Wai-Ching
authors.initials: WC
authors.lastname: Lam
authors.forename: David A L
authors.initials: DA
authors.lastname: Maberley
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003930:Diabetic Retinopathy / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D015994:Incidence; D017075:Laser Coagulation; D009885:Ophthalmology / Q000458:organization & administration*; D015995:Prevalence; D012955:Societies, Medical; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A